Gut microbiota in cardiovascular health and disease

Circulation Research

Volumn 120, Issue 7, 2017, Pages 1183-1196

  Tang, W H Wilson ^a,b   Kitai, Takeshi ^b   Hazen, Stanley L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Heart and Vascular Institute ^*  (United States)

Author keywords

cardiovascular diseases; diabetes mellitus, type 2; gastrointestinal microbiome; microbiota; trimethylamine N oxide

Indexed keywords

ANTIBIOTIC AGENT; BILE ACID; PREBIOTIC AGENT; PROBIOTIC AGENT; SHORT CHAIN FATTY ACID; TRIMETHYLAMINE; TRIMETHYLAMINE OXIDE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CHRONIC KIDNEY FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIET THERAPY; DYSBIOSIS; DYSLIPIDEMIA; ENDOCRINE GLAND; FECAL MICROBIOTA TRANSPLANTATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INTERVENTION STUDY; INTESTINE FLORA; MICROBIOME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SPLANCHNIC BLOOD FLOW; ANIMAL; DIABETES MELLITUS; METABOLISM; MICROBIOLOGY; PATHOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; GASTROINTESTINAL MICROBIOME; HUMANS;

EID: 85016760436     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.117.309715     Document Type: Review

References (193)

1. Writing Group Members Mozaffarian D, Benjamin EJ, Go AS, Writing Group Members Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 2016 133 e38 360
2. GBD 2013 Mortality and Causes of Death Collaborators Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet 2015 385 117 171.
3. Koren O, Spor A, Felin J, Fåk F, Stombaugh J, Tremaroli V, Behre CJ, Knight R, Fagerberg B, Ley RE, Bäckhed F, Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A 2011 108 suppl 1 4592 4598. doi: 10.1073/pnas.1011383107.
4. Karlsson FH, Fåk F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D, Bäckhed F, Nielsen J, Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun 2012 3 1245. doi: 10.1038/ncomms2266.
5. Yamashiro K, Tanaka R, Urabe T, Ueno Y, Yamashiro Y, Nomoto K, Takahashi T, Tsuji H, Asahara T, Hattori N, Gut dysbiosis is associated with metabolism and systemic inflammation in patients with ischemic stroke. PLoS One 2017 12 e0171521. doi: 10.1371/journal.pone.0171521.
6. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI, An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006 444 1027 1031. doi: 10.1038/nature05414.
7. Fåk F, Bäckhed F, Lactobacillus reuteri prevents diet-induced obesity, but not atherosclerosis, in a strain dependent fashion in Apoe-/- mice. PLoS One 2012 7 e46837. doi: 10.1371/journal.pone.0046837.
8. Wang Z, Klipfell E, Bennett BJ, Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011 472 57 63. doi: 10.1038/nature09922.
9. Koeth RA, Wang Z, Levison BS, Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013 19 576 585. doi: 10.1038/nm.3145.
10. Zhu W, Gregory JC, Org E, Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 2016 165 111 124. doi: 10.1016/j.cell.2016.02.011.
11. Pluznick JL, Protzko RJ, Gevorgyan H, Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci U S A 2013 110 4410 4415. doi: 10.1073/pnas.1215927110.
12. Furusawa Y, Obata Y, Fukuda S, Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013 504 446 450. doi: 10.1038/nature12721.
13. Seldin MM, Meng Y, Qi H, Zhu W, Wang Z, Hazen SL, Lusis AJ, Shih DM, Trimethylamine n-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-kappab. J Am Heart Assoc 2016 5
14. Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, Terasawa K, Kashihara D, Hirano K, Tani T, Takahashi T, Miyauchi S, Shioi G, Inoue H, Tsujimoto G, The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun 2013 4 1829. doi: 10.1038/ncomms2852.
15. De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A, Bäckhed F, Mithieux G, Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014 156 84 96. doi: 10.1016/j.cell.2013.12.016.
16. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, Cefalu WT, Ye J, Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009 58 1509 1517. doi: 10.2337/db08-1637.
17. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J, Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006 439 484 489. doi: 10.1038/nature04330.
18. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K, TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009 10 167 177. doi: 10.1016/j.cmet.2009.08.001.
19. Pols TW, Nomura M, Harach T, Lo Sasso G, Oosterveer MH, Thomas C, Rizzo G, Gioiello A, Adorini L, Pellicciari R, Auwerx J, Schoonjans K, TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 2011 14 747 757. doi: 10.1016/j.cmet.2011.11.006.
20. Ma K, Saha PK, Chan L, Moore DD, Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006 116 1102 1109. doi: 10.1172/JCI25604.
21. Downes M, Verdecia MA, Roecker AJ, Hughes R, Hogenesch JB, Kast-Woelbern HR, Bowman ME, Ferrer JL, Anisfeld AM, Edwards PA, Rosenfeld JM, Alvarez JG, Noel JP, Nicolaou KC, Evans RM, A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell 2003 11 1079 1092
22. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL, Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013 368 1575 1584. doi: 10.1056/NEJMoa1109400.
23. Neish AS, Microbes in gastrointestinal health and disease. Gastroenterology 2009 136 65 80. doi: 10.1053/j.gastro.2008.10.080.
24. Sekirov I, Russell SL, Antunes LC, Finlay BB, Gut microbiota in health and disease. Physiol Rev 2010 90 859 904. doi: 10.1152/physrev.00045.2009.
25. Nallu A, Sharma S, Ramezani A, Muralidharan J, Raj D, Gut microbiome in chronic kidney disease: challenges and opportunities. Transl Res 2017 179 24 37. doi: 10.1016/j.trsl.2016.04.007.
26. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI, Host-bacterial mutualism in the human intestine. Science 2005 307 1915 1920. doi: 10.1126/science.1104816.
27. Savage DC, Associations of indigenous microorganisms with gastrointestinal mucosal epithelia. Am J Clin Nutr 1970 23 1495 1501
28. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI, The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004 101 15718 15723. doi: 10.1073/pnas.0407076101.
29. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL, An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005 122 107 118. doi: 10.1016/j.cell.2005.05.007.
30. Li M, Wang B, Zhang M, Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A 2008 105 2117 2122. doi: 10.1073/pnas.0712038105.
31. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R, Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004 118 229 241. doi: 10.1016/j.cell.2004.07.002.
32. Qin J, Li R, Raes J, MetaHIT Consortium A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010 464 59 65. doi: 10.1038/nature08821.
33. Tamburini S, Shen N, Wu HC, Clemente JC, The microbiome in early life: implications for health outcomes. Nat Med 2016 22 713 722. doi: 10.1038/nm.4142.
34. Carmody RN, Gerber GK, Luevano JM Jr, Gatti DM, Somes L, Svenson KL, Turnbaugh PJ, Diet dominates host genotype in shaping the murine gut microbiota. Cell Host Microbe 2015 17 72 84. doi: 10.1016/j.chom.2014.11.010.
35. Tremaroli V, Bäckhed F, Functional interactions between the gut microbiota and host metabolism. Nature 2012 489 242 249. doi: 10.1038/nature11552.
36. Ley RE, Turnbaugh PJ, Klein S, Gordon JI, Microbial ecology: human gut microbes associated with obesity. Nature 2006 444 1022 1023. doi: 10.1038/4441022a.
37. Qin J, Li Y, Cai Z, A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012 490 55 60. doi: 10.1038/nature11450.
38. Ott SJ, El Mokhtari NE, Musfeldt M, Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation 2006 113 929 937. doi: 10.1161/CIRCULATIONAHA.105.579979.
39. Larsson E, Tremaroli V, Lee YS, Koren O, Nookaew I, Fricker A, Nielsen J, Ley RE, Bäckhed F, Analysis of gut microbial regulation of host gene expression along the length of the gut and regulation of gut microbial ecology through MyD88. Gut 2012 61 1124 1131. doi: 10.1136/gutjnl-2011-301104.
40. Brown JM, Hazen SL, The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. Annu Rev Med 2015 66 343 359. doi: 10.1146/annurev-med-060513-093205.
41. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM, Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009 58 1091 1103. doi: 10.1136/gut.2008.165886.
42. Cani PD, Amar J, Iglesias MA, Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007 56 1761 1772. doi: 10.2337/db06-1491.
43. Medzhitov R, Recognition of microorganisms and activation of the immune response. Nature 2007 449 819 826. doi: 10.1038/nature06246.
44. Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, Karns R, Wilson-Pérez HE, Sandoval DA, Kohli R, Bäckhed F, Seeley RJ, FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 2014 509 183 188. doi: 10.1038/nature13135.
45. Tremaroli V, Karlsson F, Werling M, Ståhlman M, Kovatcheva-Datchary P, Olbers T, Fändriks L, le Roux CW, Nielsen J, Bäckhed F, Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab 2015 22 228 238. doi: 10.1016/j.cmet.2015.07.009.
46. Perry RJ, Peng L, Barry NA, Cline GW, Zhang D, Cardone RL, Petersen KF, Kibbey RG, Goodman AL, Shulman GI, Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome. Nature 2016 534 213 217
47. Mattila KJ, Nieminen MS, Valtonen VV, Rasi VP, Kesäniemi YA, Syrjälä SL, Jungell PS, Isoluoma M, Hietaniemi K, Jokinen MJ, Association between dental health and acute myocardial infarction. BMJ 1989 298 779 781
48. Hyvärinen K, Mäntylä P, Buhlin K, Paju S, Nieminen MS, Sinisalo J, Pussinen PJ, A common periodontal pathogen has an adverse association with both acute and stable coronary artery disease. Atherosclerosis 2012 223 478 484. doi: 10.1016/j.atherosclerosis.2012.05.021.
49. Fåk F, Tremaroli V, Bergström G, Bäckhed F, Oral microbiota in patients with atherosclerosis. Atherosclerosis 2015 243 573 578. doi: 10.1016/j.atherosclerosis.2015.10.097.
50. Serra e Silva Filho W, Casarin RC, Nicolela EL Jr, Passos HM, Sallum AW, Goncalves RB, Microbial diversity similarities in periodontal pockets and atheromatous plaques of cardiovascular disease patients. PLoS One 2014 9 e109761
51. Lam V, Su J, Koprowski S, Hsu A, Tweddell JS, Rafiee P, Gross GJ, Salzman NH, Baker JE, Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J 2012 26 1727 1735. doi: 10.1096/fj.11-197921.
52. Lam V, Su J, Hsu A, Gross GJ, Salzman NH, Baker JE, Intestinal microbial metabolites are linked to severity of myocardial infarction in rats. PLoS One 2016 11 e0160840. doi: 10.1371/journal.pone.0160840.
53. Gan XT, Ettinger G, Huang CX, Burton JP, Haist JV, Rajapurohitam V, Sidaway JE, Martin G, Gloor GB, Swann JR, Reid G, Karmazyn M, Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circ Heart Fail 2014 7 491 499. doi: 10.1161/CIRCHEARTFAILURE.113.000978.
54. Tang WH, Hazen SL, The contributory role of gut microbiota in cardiovascular disease. J Clin Invest 2014 124 4204 4211. doi: 10.1172/JCI72331.
55. Koeth RA, Levison BS, Culley MK, Buffa JA, Wang Z, Gregory JC, Org E, Wu Y, Li L, Smith JD, Tang WH, DiDonato JA, Lusis AJ, Hazen SL, γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab 2014 20 799 812. doi: 10.1016/j.cmet.2014.10.006.
56. Craciun S, Balskus EP, Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc Natl Acad Sci U S A 2012 109 21307 21312. doi: 10.1073/pnas.1215689109.
57. Chen Y, Patel NA, Crombie A, Scrivens JH, Murrell JC, Bacterial flavin-containing monooxygenase is trimethylamine monooxygenase. Proc Natl Acad Sci U S A 2011 108 17791 17796. doi: 10.1073/pnas.1112928108.
58. Bennett BJ, de Aguiar Vallim TQ, Wang Z, Shih DM, Meng Y, Gregory J, Allayee H, Lee R, Graham M, Crooke R, Edwards PA, Hazen SL, Lusis AJ, Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab 2013 17 49 60. doi: 10.1016/j.cmet.2012.12.011.
59. Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, Li XS, Levison BS, Hazen SL, Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 2015 116 448 455. doi: 10.1161/CIRCRESAHA.116.305360.
60. Tang WH, Wang Z, Fan Y, Levison B, Hazen JE, Donahue LM, Wu Y, Hazen SL, Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol 2014 64 1908 1914. doi: 10.1016/j.jacc.2014.02.617.
61. Tang WH, Wang Z, Shrestha K, Borowski AG, Wu Y, Troughton RW, Klein AL, Hazen SL, Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. J Card Fail 2015 21 91 96. doi: 10.1016/j.cardfail.2014.11.006.
62. Senthong V, Wang Z, Fan Y, Wu Y, Hazen SL, Tang WH, Trimethylamine n-oxide and mortality risk in patients with peripheral artery disease. J Am Heart Assoc 2016 5 e004237. doi: 10.1161/JAHA.116.004237.
63. Fu Q, Zhao M, Wang D, Hu H, Guo C, Chen W, Li Q, Zheng L, Chen B, Coronary plaque characterization assessed by optical coherence tomography and plasma trimethylamine-N-oxide levels in patients with coronary artery disease. Am J Cardiol 2016 118 1311 1315. doi: 10.1016/j.amjcard.2016.07.071.
64. Li XS, Obeid S, Klingenberg R, Gencer B, Mach F, Raber L, Windecker S, Rodondi N, Nanchen D, Muller O, Miranda MX, Matter CM, Wu Y, Li L, Wang Z, Alamri HS, Gogonea V, Chung YM, Tang WH, Hazen SL, Luscher TF, Gut microbiota-dependent trimethylamine n-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur Heart J 2017 11
65. Wang Z, Roberts AB, Buffa JA, Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 2015 163 1585 1595. doi: 10.1016/j.cell.2015.11.055.
66. Honour J, The possible involvement of intestinal bacteria in steroidal hypertension. Endocrinology 1982 110 285 287. doi: 10.1210/endo-110-1-285.
67. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, Zadeh M, Gong M, Qi Y, Zubcevic J, Sahay B, Pepine CJ, Raizada MK, Mohamadzadeh M, Gut dysbiosis is linked to hypertension. Hypertension 2015 65 1331 1340. doi: 10.1161/HYPERTENSIONAHA.115.05315.
68. Mell B, Jala VR, Mathew AV, Byun J, Waghulde H, Zhang Y, Haribabu B, Vijay-Kumar M, Pennathur S, Joe B, Evidence for a link between gut microbiota and hypertension in the Dahl rat. Physiol Genomics 2015 47 187 197. doi: 10.1152/physiolgenomics.00136.2014.
69. Qi Y, Aranda JM, Rodriguez V, Raizada MK, Pepine CJ, Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension-A case report. Int J Cardiol 2015 201 157 158. doi: 10.1016/j.ijcard.2015.07.078.
70. Adnan S, Nelson JW, Ajami NJ, Venna VR, Petrosino JF, Bryan RM Jr, Durgan DJ, Alterations in the gut microbiota can elicit hypertension in rats. Physiol Genomics 2017 49 96 104. doi: 10.1152/physiolgenomics.00081.2016.
71. Karbach SH, Schonfelder T, Brandao I, Wilms E, Hormann N, Jackel S, Schuler R, Finger S, Knorr M, Lagrange J, Brandt M, Waisman A, Kossmann S, Schafer K, Munzel T, Reinhardt C, Wenzel P, Gut microbiota promote angiotensin ii-induced arterial hypertension and vascular dysfunction. J Am Heart Assoc 2016 5
72. Gomez-Arango LF, Barrett HL, McIntyre HD, Callaway LK, Morrison M, Dekker Nitert M, SPRING Trial Group Increased systolic and diastolic blood pressure is associated with altered gut microbiota composition and butyrate production in early pregnancy. Hypertension 2016 68 974 981. doi: 10.1161/HYPERTENSIONAHA.116.07910.
73. Evans JM, Morris LS, Marchesi JR, The gut microbiome: the role of a virtual organ in the endocrinology of the host. J Endocrinol 2013 218 R37 R47. doi: 10.1530/JOE-13-0131.
74. Pluznick JL, Renal and cardiovascular sensory receptors and blood pressure regulation. Am J Physiol Renal Physiol 2013 305 F439 F444. doi: 10.1152/ajprenal.00252.2013.
75. Sharkey KA, Savidge TC, Role of enteric neurotransmission in host defense and protection of the gastrointestinal tract. Auton Neurosci 2014 181 94 106. doi: 10.1016/j.autneu.2013.12.006.
76. Santisteban MM, Qi Y, Zubcevic J, Kim S, Yang T, Shenoy V, Cole-Jeffrey CT, Lobaton GO, Stewart DC, Rubiano A, Simmons CS, Garcia-Pereira F, Johnson RD, Pepine CJ, Raizada MK, Hypertension-linked pathophysiological alterations in the gut. Circ Res 2017 120 312 323. doi: 10.1161/CIRCRESAHA.116.309006.
77. Pålsson J, Ricksten SE, Delle M, Lundin S, Changes in renal sympathetic nerve activity during experimental septic and endotoxin shock in conscious rats. Circ Shock 1988 24 133 141
78. Straub RH, Pongratz G, Weidler C, Linde HJ, Kirschning CJ, Glück T, Schölmerich J, Falk W, Ablation of the sympathetic nervous system decreases gram-negative and increases gram-positive bacterial dissemination: key roles for tumor necrosis factor/phagocytes and interleukin-4/lymphocytes. J Infect Dis 2005 192 560 572. doi: 10.1086/432134.
79. Diaz Heijtz R, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, Hibberd ML, Forssberg H, Pettersson S, Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A 2011 108 3047 3052. doi: 10.1073/pnas.1010529108.
80. Kawase M, Hashimoto H, Hosoda M, Morita H, Hosono A, Effect of administration of fermented milk containing whey protein concentrate to rats and healthy men on serum lipids and blood pressure. J Dairy Sci 2000 83 255 263. doi: 10.3168/jds.S0022-0302(00)74872-7.
81. Tanida M, Yamano T, Maeda K, Okumura N, Fukushima Y, Nagai K, Effects of intraduodenal injection of Lactobacillus johnsonii La1 on renal sympathetic nerve activity and blood pressure in urethane-anesthetized rats. Neurosci Lett 2005 389 109 114. doi: 10.1016/j.neulet.2005.07.036.
82. Gómez-Guzmán M, Toral M, Romero M, Jiménez R, Galindo P, Sánchez M, Zarzuelo MJ, Olivares M, Gálvez J, Duarte J, Antihypertensive effects of probiotics Lactobacillus strains in spontaneously hypertensive rats. Mol Nutr Food Res 2015 59 2326 2336. doi: 10.1002/mnfr.201500290.
83. Khalesi S, Sun J, Buys N, Jayasinghe R, Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension 2014 64 897 903. doi: 10.1161/HYPERTENSIONAHA.114.03469.
84. Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, Schroedl W, Karhausen T, Doehner W, Rauchhaus M, Poole-Wilson P, Volk HD, Lochs H, Anker SD, Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 2007 50 1561 1569. doi: 10.1016/j.jacc.2007.07.016.
85. Krack A, Richartz BM, Gastmann A, Greim K, Lotze U, Anker SD, Figulla HR, Studies on intragastric PCO2 at rest and during exercise as a marker of intestinal perfusion in patients with chronic heart failure. Eur J Heart Fail 2004 6 403 407. doi: 10.1016/j.ejheart.2004.03.002.
86. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJ, Anker SD, Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999 353 1838 1842. doi: 10.1016/S0140-6736(98)09286-1.
87. Sandek A, Swidsinski A, Schroedl W, Watson A, Valentova M, Herrmann R, Scherbakov N, Cramer L, Rauchhaus M, Grosse-Herrenthey A, Krueger M, von Haehling S, Doehner W, Anker SD, Bauditz J, Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia. J Am Coll Cardiol 2014 64 1092 1102. doi: 10.1016/j.jacc.2014.06.1179.
88. Pasini E, Aquilani R, Testa C, Baiardi P, Angioletti S, Boschi F, Verri M, Dioguardi F, Pathogenic gut flora in patients with chronic heart failure. JACC Heart Fail 2016 4 220 227. doi: 10.1016/j.jchf.2015.10.009.
89. Wang Z, Tang WH, Buffa JA, Fu X, Britt EB, Koeth RA, Levison BS, Fan Y, Wu Y, Hazen SL, Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J 2014 35 904 910. doi: 10.1093/eurheartj/ehu002.
90. Organ CL, Otsuka H, Bhushan S, Wang Z, Bradley J, Trivedi R, Polhemus DJ, Tang WH, Wu Y, Hazen SL, Lefer DJ, Choline diet and its gut microbe-derived metabolite, trimethylamine N-oxide, exacerbate pressure overload-induced heart failure. Circ Heart Fail 2016 9 e002314. doi: 10.1161/CIRCHEARTFAILURE.115.002314.
91. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI, Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005 102 11070 11075. doi: 10.1073/pnas.0504978102.
92. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI, A core gut microbiome in obese and lean twins. Nature 2009 457 480 484. doi: 10.1038/nature07540.
93. Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, Nielsen J, Bäckhed F, Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013 498 99 103. doi: 10.1038/nature12198.
94. Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sørensen SJ, Hansen LH, Jakobsen M, Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010 5 e9085. doi: 10.1371/journal.pone.0009085.
95. Donohoe DR, Garge N, Zhang X, Sun W, O'Connell TM, Bunger MK, Bultman SJ, The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab 2011 13 517 526. doi: 10.1016/j.cmet.2011.02.018.
96. Donohoe DR, Wali A, Brylawski BP, Bultman SJ, Microbial regulation of glucose metabolism and cell-cycle progression in mammalian colonocytes. PLoS One 2012 7 e46589. doi: 10.1371/journal.pone.0046589.
97. Meyer TW, Hostetter TH, Uremic solutes from colon microbes. Kidney Int 2012 81 949 954. doi: 10.1038/ki.2011.504.
98. Schwiertz A, Taras D, Schäfer K, Beijer S, Bos NA, Donus C, Hardt PD, Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 2010 18 190 195. doi: 10.1038/oby.2009.167.
99. Vrieze A, Out C, Fuentes S, Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol 2014 60 824 831. doi: 10.1016/j.jhep.2013.11.034.
100. Sharma M, Thandassery RB, Bhargava N, Double pylorus: an optical illusion or reality? Gastroenterology 2012 143 e7 e8. doi: 10.1053/j.gastro.2012.01.053.
101. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, Schilter HC, Rolph MS, Mackay F, Artis D, Xavier RJ, Teixeira MM, Mackay CR, Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009 461 1282 1286. doi: 10.1038/nature08530.
102. Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, Hammer RE, Williams SC, Crowley J, Yanagisawa M, Gordon JI, Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci U S A 2008 105 16767 16772. doi: 10.1073/pnas.0808567105.
103. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F, Gribble FM, Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 2012 61 364 371. doi: 10.2337/db11-1019.
104. Fava S, Glucagon-like peptide 1 and the cardiovascular system. Curr Diabetes Rev 2014 10 302 310
105. Chambers ES, Viardot A, Psichas A, Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut 2015 64 1744 1754. doi: 10.1136/gutjnl-2014-307913.
106. Freeland KR, Wolever TM, Acute effects of intravenous and rectal acetate on glucagon-like peptide-1, peptide YY, ghrelin, adiponectin and tumour necrosis factor-alpha. Br J Nutr 2010 103 460 466. doi: 10.1017/S0007114509991863.
107. Midtvedt T, Microbial bile acid transformation. Am J Clin Nutr 1974 27 1341 1347
108. Russell DW, The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003 72 137 174. doi: 10.1146/annurev.biochem.72.121801.161712.
109. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K, Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008 7 678 693. doi: 10.1038/nrd2619.
110. Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P, Bile acids as regulatory molecules. J Lipid Res 2009 50 1509 1520. doi: 10.1194/jlr.R900007-JLR200.
111. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B, Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009 89 147 191. doi: 10.1152/physrev.00010.2008.
112. Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F, Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013 17 225 235. doi: 10.1016/j.cmet.2013.01.003.
113. Li F, Jiang C, Krausz KW, Li Y, Albert I, Hao H, Fabre KM, Mitchell JB, Patterson AD, Gonzalez FJ, Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 2013 4 2384. doi: 10.1038/ncomms3384.
114. Jiang C, Xie C, Li F, Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 2015 125 386 402. doi: 10.1172/JCI76738.
115. Islam KB, Fukiya S, Hagio M, Fujii N, Ishizuka S, Ooka T, Ogura Y, Hayashi T, Yokota A, Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 2011 141 1773 1781. doi: 10.1053/j.gastro.2011.07.046.
116. Kurdi P, Kawanishi K, Mizutani K, Yokota A, Mechanism of growth inhibition by free bile acids in lactobacilli and bifidobacteria. J Bacteriol 2006 188 1979 1986. doi: 10.1128/JB.188.5.1979-1986.2006.
117. Ahmad NN, Pfalzer A, Kaplan LM, Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. Int J Obes (Lond) 2013 37 1553 1559. doi: 10.1038/ijo.2013.38.
118. Kohli R, Bradley D, Setchell KD, Eagon JC, Abumrad N, Klein S, Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab 2013 98 E708 E712. doi: 10.1210/jc.2012-3736.
119. Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, Badman MK, Maratos-Flier E, Mun EC, Pihlajamaki J, Auwerx J, Goldfine AB, Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 2009 17 1671 1677. doi: 10.1038/oby.2009.102.
120. Nakatani H, Kasama K, Oshiro T, Watanabe M, Hirose H, Itoh H, Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. Metabolism 2009 58 1400 1407. doi: 10.1016/j.metabol.2009.05.006.
121. Pournaras DJ, Glicksman C, Vincent RP, Kuganolipava S, Alaghband-Zadeh J, Mahon D, Bekker JH, Ghatei MA, Bloom SR, Walters JR, Welbourn R, le Roux CW, The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 2012 153 3613 3619. doi: 10.1210/en.2011-2145.
122. Simonen M, Dali-Youcef N, Kaminska D, Venesmaa S, Käkelä P, Pääkkönen M, Hallikainen M, Kolehmainen M, Uusitupa M, Moilanen L, Laakso M, Gylling H, Patti ME, Auwerx J, Pihlajamäki J, Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. Obes Surg 2012 22 1473 1480. doi: 10.1007/s11695-012-0673-5.
123. le Roux CW, Bloom SR, Why do patients lose weight after Roux-en-Y gastric bypass? J Clin Endocrinol Metab 2005 90 591 592. doi: 10.1210/jc.2004-2211.
124. Miras AD, le Roux CW, Mechanisms underlying weight loss after bariatric surgery. Nat Rev Gastroenterol Hepatol 2013 10 575 584. doi: 10.1038/nrgastro.2013.119.
125. Fu J, Bonder MJ, Cenit MC, The gut microbiome contributes to a substantial proportion of the variation in blood lipids. Circ Res 2015 117 817 824. doi: 10.1161/CIRCRESAHA.115.306807.
126. Shih DM, Wang Z, Lee R, Meng Y, Che N, Charugundla S, Qi H, Wu J, Pan C, Brown JM, Vallim T, Bennett BJ, Graham M, Hazen SL, Lusis AJ, Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res 2015 56 22 37. doi: 10.1194/jlr.M051680.
127. Warrier M, Shih DM, Burrows AC, Ferguson D, Gromovsky AD, Brown AL, Marshall S, McDaniel A, Schugar RC, Wang Z, Sacks J, Rong X, Vallim TA, Chou J, Ivanova PT, Myers DS, Brown HA, Lee RG, Crooke RM, Graham MJ, Liu X, Parini P, Tontonoz P, Lusis AJ, Hazen SL, Temel RE, Brown JM, The tmao-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance. Cell Rep 2015 14 01065 01061
128. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R, Cardiorenal syndrome. J Am Coll Cardiol 2008 52 1527 1539. doi: 10.1016/j.jacc.2008.07.051.
129. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP, Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013 382 339 352. doi: 10.1016/S0140-6736(13)60595-4.
130. Schnabel R, Blankenberg S, Oxidative stress in cardiovascular disease: successful translation from bench to bedside? Circulation 2007 116 1338 1340. doi: 10.1161/CIRCULATIONAHA.107.728394.
131. Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen TH, Andersen GL, Chronic kidney disease alters intestinal microbial flora. Kidney Int 2013 83 308 315. doi: 10.1038/ki.2012.345.
132. Wong J, Piceno YM, Desantis TZ, Pahl M, Andersen GL, Vaziri ND, Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol 2014 39 230 237. doi: 10.1159/000360010.
133. Szeto CC, Kwan BC, Chow KM, Lai KB, Chung KY, Leung CB, Li PK, Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol 2008 3 431 436. doi: 10.2215/CJN.03600807.
134. Shi K, Wang F, Jiang H, Liu H, Wei M, Wang Z, Xie L, Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. Dig Dis Sci 2014 59 2109 2117. doi: 10.1007/s10620-014-3202-7.
135. Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, Verbeke K, Kuypers D, Vanrenterghem Y, Evenepoel P, p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010 5 1182 1189. doi: 10.2215/CJN.07971109.
136. Koppe L, Pillon NJ, Vella RE, Croze ML, Pelletier CC, Chambert S, Massy Z, Glorieux G, Vanholder R, Dugenet Y, Soula HA, Fouque D, Soulage CO, p-Cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol 2013 24 88 99. doi: 10.1681/ASN.2012050503.
137. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA, European Uremic Toxin Work Group (EUTox) Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009 4 1551 1558. doi: 10.2215/CJN.03980609.
138. Devlin AS, Marcobal A, Dodd D, Nayfach S, Plummer N, Meyer T, Pollard KS, Sonnenburg JL, Fischbach MA, Modulation of a circulating uremic solute via rational genetic manipulation of the gut microbiota. Cell Host Microbe 2016 20 709 715. doi: 10.1016/j.chom.2016.10.021.
139. Wang CP, Lu LF, Yu TH, Hung WC, Chiu CA, Chung FM, Yeh LR, Chen HJ, Lee YJ, Houng JY, Serum levels of total p-cresylsulphate are associated with angiographic coronary atherosclerosis severity in stable angina patients with early stage of renal failure. Atherosclerosis 2010 211 579 583. doi: 10.1016/j.atherosclerosis.2010.03.036.
140. Rhee EP, Clish CB, Ghorbani A, A combined epidemiologic and metabolomic approach improves CKD prediction. J Am Soc Nephrol 2013 24 1330 1338. doi: 10.1681/ASN.2012101006.
141. Colman RJ, Rubin DT, Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 2014 8 1569 1581. doi: 10.1016/j.crohns.2014.08.006.
142. Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, Park T, Stollman N, Rohlke F, Surawicz C, Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012 107 1079 1087. doi: 10.1038/ajg.2012.60.
143. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ, Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013 368 407 415. doi: 10.1056/NEJMoa1205037.
144. Vrieze A, Van Nood E, Holleman F, Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012 143 913 6.e7. doi: 10.1053/j.gastro.2012.06.031.
145. Gregory JC, Buffa JA, Org E, Wang Z, Levison BS, Zhu W, Wagner MA, Bennett BJ, Li L, DiDonato JA, Lusis AJ, Hazen SL, Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem 2015 290 5647 5660. doi: 10.1074/jbc.M114.618249.
146. Brandt LJ, FMT: first step in a long journey. Am J Gastroenterol 2013 108 1367 1368. doi: 10.1038/ajg.2013.165.
147. De Leon LM, Watson JB, Kelly CR, Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2013 11 1036 1038. doi: 10.1016/j.cgh.2013.04.045.
148. Wymore Brand M, Wannemuehler MJ, Phillips GJ, Proctor A, Overstreet AM, Jergens AE, Orcutt RP, Fox JG, The Altered Schaedler Flora: Continued Applications of a Defined Murine Microbial Community. ILAR J 2015 56 169 178. doi: 10.1093/ilar/ilv012.
149. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N, A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997 336 1117 1124. doi: 10.1056/NEJM199704173361601.
150. Estruch R, Ros E, Salas-Salvadó J, PREDIMED Study Investigators Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013 368 1279 1290. doi: 10.1056/NEJMoa1200303.
151. Zeevi D, Korem T, Zmora N, Personalized nutrition by prediction of glycemic responses. Cell 2015 163 1079 1094. doi: 10.1016/j.cell.2015.11.001.
152. Xu Z, Knight R, Dietary effects on human gut microbiome diversity. Br J Nutr 2015 113 Suppl S1 S5. doi: 10.1017/S0007114514004127.
153. Voreades N, Kozil A, Weir TL, Diet and the development of the human intestinal microbiome. Front Microbiol 2014 5 494. doi: 10.3389/fmicb.2014.00494.
154. Ravussin Y, Koren O, Spor A, LeDuc C, Gutman R, Stombaugh J, Knight R, Ley RE, Leibel RL, Responses of gut microbiota to diet composition and weight loss in lean and obese mice. Obesity (Silver Spring) 2012 20 738 747. doi: 10.1038/oby.2011.111.
155. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ, Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014 505 559 563. doi: 10.1038/nature12820.
156. Duncan SH, Belenguer A, Holtrop G, Johnstone AM, Flint HJ, Lobley GE, Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl Environ Microbiol 2007 73 1073 1078. doi: 10.1128/AEM.02340-06.
157. Duncan SH, Lobley GE, Holtrop G, Ince J, Johnstone AM, Louis P, Flint HJ, Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes (Lond) 2008 32 1720 1724. doi: 10.1038/ijo.2008.155.
158. Foye OT, Huang IF, Chiou CC, Walker WA, Shi HN, Early administration of probiotic Lactobacillus acidophilus and/or prebiotic inulin attenuates pathogen-mediated intestinal inflammation and Smad 7 cell signaling. FEMS Immunol Med Microbiol 2012 65 467 480. doi: 10.1111/j.1574-695X.2012.00978.x.
159. Marques FZ, Nelson EM, Chu PY, Horlock D, Fiedler A, Ziemann M, Tan JK, Kuruppu S, Rajapakse NW, El-Osta A, Mackay CR, Kaye DM, High fibre diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in doca-salt hypertensive mice. Circulation 2016 7 024545
160. Xiao S, Fei N, Pang X, A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. FEMS Microbiol Ecol 2014 87 357 367. doi: 10.1111/1574-6941.12228.
161. den Besten G, Bleeker A, Gerding A, van Eunen K, Havinga R, van Dijk TH, Oosterveer MH, Jonker JW, Groen AK, Reijngoud DJ, Bakker BM, Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation. Diabetes 2015 64 2398 2408. doi: 10.2337/db14-1213.
162. Frost G, Sleeth ML, Sahuri-Arisoylu M, The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun 2014 5 3611. doi: 10.1038/ncomms4611.
163. Shoaie S, Ghaffari P, Kovatcheva-Datchary P, MICRO-Obes Consortium Quantifying diet-induced metabolic changes of the human gut microbiome. Cell Metab 2015 22 320 331. doi: 10.1016/j.cmet.2015.07.001.
164. Ojetti V, Lauritano EC, Barbaro F, Migneco A, Ainora ME, Fontana L, Gabrielli M, Gasbarrini A, Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol 2009 5 675 682. doi: 10.1517/17425250902973695.
165. Goodrich JK, Waters JL, Poole AC, Sutter JL, Koren O, Blekhman R, Beaumont M, Van Treuren W, Knight R, Bell JT, Spector TD, Clark AG, Ley RE, Human genetics shape the gut microbiome. Cell 2014 159 789 799. doi: 10.1016/j.cell.2014.09.053.
166. Simon MC, Strassburger K, Nowotny B, Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept. Diabetes Care 2015 38 1827 1834. doi: 10.2337/dc14-2690.
167. Simenhoff ML, Dunn SR, Zollner GP, Fitzpatrick ME, Emery SM, Sandine WE, Ayres JW, Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. Miner Electrolyte Metab 1996 22 92 96
168. Karlsson C, Ahrné S, Molin G, Berggren A, Palmquist I, Fredrikson GN, Jeppsson B, Probiotic therapy to men with incipient arteriosclerosis initiates increased bacterial diversity in colon: a randomized controlled trial. Atherosclerosis 2010 208 228 233. doi: 10.1016/j.atherosclerosis.2009.06.019.
169. Chen Z, Guo L, Zhang Y, Walzem RL, Pendergast JS, Printz RL, Morris LC, Matafonova E, Stien X, Kang L, Coulon D, McGuinness OP, Niswender KD, Davies SS, Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. J Clin Invest 2014 124 3391 3406. doi: 10.1172/JCI72517.
170. Lallès JP, Intestinal alkaline phosphatase: multiple biological roles in maintenance of intestinal homeostasis and modulation by diet. Nutr Rev 2010 68 323 332. doi: 10.1111/j.1753-4887.2010.00292.x.
171. Jones ML, Martoni CJ, Prakash S, Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. Eur J Clin Nutr 2012 66 1234 1241. doi: 10.1038/ejcn.2012.126.
172. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM, Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007 50 2374 2383. doi: 10.1007/s00125-007-0791-0.
173. Robertson MD, Bickerton AS, Dennis AL, Vidal H, Frayn KN, Insulin-sensitizing effects of dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism. Am J Clin Nutr 2005 82 559 567
174. Parnell JA, Reimer RA, Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 2009 89 1751 1759. doi: 10.3945/ajcn.2009.27465.
175. Everard A, Lazarevic V, Derrien M, Girard M, Muccioli GG, Muccioli GM, Neyrinck AM, Possemiers S, Van Holle A, François P, de Vos WM, Delzenne NM, Schrenzel J, Cani PD, Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 2011 60 2775 2786. doi: 10.2337/db11-0227.
176. Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM, Bindels LB, de Vos WM, Gibson GR, Thissen JP, Delzenne NM, Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 2013 62 1112 1121. doi: 10.1136/gutjnl-2012-303304.
177. Salonen A, Lahti L, Salojärvi J, Holtrop G, Korpela K, Duncan SH, Date P, Farquharson F, Johnstone AM, Lobley GE, Louis P, Flint HJ, de Vos WM, Impact of diet and individual variation on intestinal microbiota composition and fermentation products in obese men. ISME J 2014 8 2218 2230. doi: 10.1038/ismej.2014.63.
178. Trasande L, Blustein J, Liu M, Corwin E, Cox LM, Blaser MJ, Infant antibiotic exposures and early-life body mass. Int J Obes (Lond) 2013 37 16 23. doi: 10.1038/ijo.2012.132.
179. Cho I, Yamanishi S, Cox L, Methé BA, Zavadil J, Li K, Gao Z, Mahana D, Raju K, Teitler I, Li H, Alekseyenko AV, Blaser MJ, Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 2012 488 621 626. doi: 10.1038/nature11400.
180. Stepankova R, Tonar Z, Bartova J, Nedorost L, Rossman P, Poledne R, Schwarzer M, Tlaskalova-Hogenova H, Absence of microbiota (germ-free conditions) accelerates the atherosclerosis in ApoE-deficient mice fed standard low cholesterol diet. J Atheroscler Thromb 2010 17 796 804
181. Pluznick J, A novel scfa receptor, the microbiota, and blood pressure regulation. Gut Microbes 2014 5 202 207
182. Holmes E, Li JV, Marchesi JR, Nicholson JK, Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab 2012 16 559 564. doi: 10.1016/j.cmet.2012.10.007.
183. Turnbaugh PJ, Gordon JI, The core gut microbiome, energy balance and obesity. J Physiol 2009 587 4153 4158. doi: 10.1113/jphysiol.2009.174136.
184. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI, Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007 104 979 984. doi: 10.1073/pnas.0605374104.
185. Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, Tzen CY, Wang YC, Lin CY, Wu MS, p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2011 26 938 947. doi: 10.1093/ndt/gfq580.
186. Lin CJ, Chen HH, Pan CF, Chuang CK, Wang TJ, Sun FJ, Wu CJ, p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. J Clin Lab Anal 2011 25 191 197. doi: 10.1002/jcla.20456.
187. Watanabe H, Miyamoto Y, Honda D, p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int 2013 83 582 592. doi: 10.1038/ki.2012.448.
188. Walser M, Bodenlos LJ, Urea metabolism in man. J Clin Invest 1959 38 1617 1626. doi: 10.1172/JCI103940.
189. Suzuki T, Heaney LM, Jones DJ, Ng LL, Trimethylamine N-oxide and risk stratification after acute myocardial infarction. Clin Chem 2017 63 420 428. doi: 10.1373/clinchem.2016.264853.
190. Ufnal M, Jazwiec R, Dadlez M, Drapala A, Sikora M, Skrzypecki J, Trimethylamine-N-oxide: a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin II in rats. Can J Cardiol 2014 30 1700 1705. doi: 10.1016/j.cjca.2014.09.010.
191. Tang WH, Wang Z, Li XS, Fan Y, Li DS, Wu Y, Hazen SL, Increased trimethylamine N-oxide portends high mortality risk independent of glycemic control in patients with type 2 diabetes mellitus. Clin Chem 2017 63 297 306. doi: 10.1373/clinchem.2016.263640.
192. Stubbs JR, House JA, Ocque AJ, Zhang S, Johnson C, Kimber C, Schmidt K, Gupta A, Wetmore JB, Nolin TD, Spertus JA, Yu AS, Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden. J Am Soc Nephrol 2016 27 305 313. doi: 10.1681/ASN.2014111063.
193. Tachon S, Lee B, Marco ML, Diet alters probiotic Lactobacillus persistence and function in the intestine. Environ Microbiol 2014 16 2915 2926. doi: 10.1111/1462-2920.12297.